UNICA IRIS Institutional Research Information System

DEMELIA, LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 96.249
NA - Nord America 4.266
AS - Asia 518
AF - Africa 8
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 1
Totale 101.045
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 94.774
US - Stati Uniti d'America 4.247
UA - Ucraina 542
CN - Cina 455
SE - Svezia 286
DE - Germania 273
FI - Finlandia 145
GB - Regno Unito 128
FR - Francia 40
RU - Federazione Russa 29
SG - Singapore 25
CA - Canada 18
VN - Vietnam 16
BE - Belgio 13
IN - India 4
NL - Olanda 4
PK - Pakistan 4
DK - Danimarca 3
EU - Europa 3
KR - Corea 3
MA - Marocco 3
CZ - Repubblica Ceca 2
IL - Israele 2
MU - Mauritius 2
NG - Nigeria 2
AT - Austria 1
CH - Svizzera 1
CL - Cile 1
ES - Italia 1
HK - Hong Kong 1
ID - Indonesia 1
IE - Irlanda 1
IR - Iran 1
JP - Giappone 1
LB - Libano 1
LU - Lussemburgo 1
MN - Mongolia 1
MY - Malesia 1
NO - Norvegia 1
PA - Panama 1
PL - Polonia 1
PT - Portogallo 1
RO - Romania 1
SD - Sudan 1
SI - Slovenia 1
TR - Turchia 1
TW - Taiwan 1
Totale 101.045
Salva come PNG Salva come JPEG
Città #
Cagliari 94.514
Fairfield 549
Woodbridge 426
Chandler 385
Houston 336
Ann Arbor 335
Jacksonville 287
Wilmington 247
Ashburn 240
Dearborn 222
Nyköping 220
Cambridge 215
Seattle 193
Boardman 93
Nanjing 87
Helsinki 65
Boston 62
New York 54
Beijing 47
Shanghai 45
Nanchang 36
Milan 34
San Diego 32
Shenyang 30
Hebei 27
Verona 26
Jiaxing 25
Guangzhou 22
Hefei 21
Changsha 20
Orange 20
Toronto 17
Auburn Hills 16
Dong Ket 16
Mountain View 16
Redwood City 16
Brussels 13
London 13
Norwalk 13
Tianjin 13
Jinan 12
Kunming 12
Ningbo 11
Washington 10
Rome 9
Ansbach 8
Sassari 8
Taizhou 6
Zhengzhou 6
Los Angeles 5
Perugia 5
Saint Petersburg 5
Atlanta 4
Borås 4
Lahore 4
Chengdu 3
Hangzhou 3
Paris 3
Quartu Sant'elena 3
Redmond 3
San Jose 3
Chiswick 2
Columbus 2
Guasila 2
Hounslow 2
Islington 2
Kilburn 2
Murello 2
Naples 2
Phoenix 2
San Francisco 2
Singapore 2
Southwark 2
Turin 2
Walnut 2
Wandsworth 2
Wuhan 2
Alghero 1
Amsterdam 1
Aurora 1
Baotou 1
Beaverton 1
Brescia 1
Brooklyn 1
Cedar Knolls 1
Central District 1
Chicago 1
Concepción 1
Costa Mesa 1
Dallas 1
Dongguan 1
Dublin 1
Easton 1
El Segundo 1
Elkridge 1
Ellenwood 1
Esslingen am Neckar 1
Frankfurt am Main 1
Frederiksberg 1
Fuzhou 1
Totale 99.230
Salva come PNG Salva come JPEG
Nome #
Proteomic investigation of whole saliva in Wilson's disease 4.003
null 3.544
Bipolar disorders and Wilson's disease 2.797
The burden of depressive and bipolar disorders in celiac disease 2.718
Coeliac disease and psychiatric comorbidity: epidemiology, pathophysiological mechanisms, quality-of-life, and gluten-free diet effects 2.427
Premature vascular deterioration in young patients affected by Wilson's disease: a pilot study 2.302
Homogeneous magnetic resonance imaging of brain abnormalities in bipolar spectrum disorders comorbid with Wilson's disease 2.238
Mutation analysis of the ATP7B gene in a new group of Wilson's disease patients: Contribution to diagnosis. 2.223
Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis? 2.220
Late onset Wilson's disease 2.142
Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson's disease 2.101
A Top-Down proteomic study of the whole saliva of subjects affected by Wilson disease reveals qualitative and quantitative alterations of the S100A8 and S100A9 proteins 2.094
Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena 2.075
Psychiatric comorbidity in Wilson’s disease 2.007
Potential biomarker discover of the Wilson’s disease by top-down proteomic investigation of whole saliva 1.941
Value of histochemical stains for copper in the diagnosis of Wilson's disease 1.830
Quality of life and psychiatric symptoms in wilson's disease: The relevance of bipolar disorders 1.815
Histologic evolution and long-term outcome of Wilson's disease: results of a single-center experience 1.794
The relationship between copper and steatosis in Wilson's disease 1.728
null 1.710
TT virus infection in Italy: prevalence and genotypes in healthy subjects, viral liver diseases and asymptomatic infections by parenterally transmitted viruses 1.709
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D 1.685
Non-invasive assessment of silent liver fibrosis in patients with systemic sclerosis 1.680
A randomized controlled trial of sequential pegylated interferon-alpha and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B 1.633
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort 1.599
Kayser-Fleischer ring in Wilson's disease: a cohort study 1.474
Non-invasive assessment of hepatic fibrosis in a series of patients with Wilson's Disease 1.433
Uneven hepatic copper distribution in Wilson's disease 1.428
Reversibility of fibrosis in Wilson disease 1.386
HBV and HCV infections in Wilson's disease patients: Copper overload could be protective? 1.376
null 1.366
Secondary RBD in a patient affected by chronic hepatic encephalopathy: a case report. 1.341
Brain MR spectroscopy in the evaluation of Wilson's disease: Correlation with clinical status and response to therapy 1.324
Dynamic 99mTc-HIDA hepatobiliary scintigraphy in vanishing bile duct syndrome 1.172
Peginterferon-alpha-2a plus adefovir vs. peginterferon alpha-2a for 48 weeks in hbeag-negative chronic hepatitis B: Preliminary 24-week results of the peg for B randomized multicenter trial 1.126
Usefulness of dynamic hepatobiliary scintigraphy in Wilson's disease 1.080
Patterns of chronic hepatitis B in Central Italy: a cross-sectional study. 1.058
Wilson’s disease with late onset 947
Tolerability of Peg interferon-alpha 2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency 928
Animal models are reliably mimicking human diseases? A morphological study that compares animal with human NAFLD 910
HFE gene mutations and Wilson's disease in Sardinia 909
Plasma prekallikrein (Fletcher factor) in hepatic cirrhosis 885
[Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy]. FT Effetto a breve termine della terapia con DL-carnitina per os ed L-carnitina e.v. nei pazienti uremici cronici in trattamento emodialitico. 881
Resolved Psychosis after Liver Transplantation in a Patient with Wilson's Disease 866
Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy 849
HFE gene mutations and Wilson's disease in Sardinia 838
A randomized controlled trial of pegylated interferon-alpha 2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B 833
Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study 832
Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson's disease 827
SEQUENTIAL PEGINTERFERON ALPHA-2A AND TELBIVUDINE OR VICE VERSA FOR HBEAG-NEGATIVE CHRONIC HEPATITIS B: PRELIMINARY END-OF-TREATMENT RESULTS OF THE TEL-B-PEG RANDOMIZED TRIAL 816
Massive haemosiderosis in Wilson’s disease 791
Clinical features of Wilson's disease in Sardinia 781
A randomized controlled trial of amantadine plus interferon-alpha 2a vs. interferon-alpha 2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha 2a monotherapy 763
Interferon beta-1a alone or in combination with ribavirin: A randomized trial to compare efficacy and safety in chronic hepatitis C 754
Massive haemosiderosis in Wilson's disease - Reply 691
Fine structure of hepatic sinusoids in Wilson’s disease. A scanning electron microscopic study 683
Massive hepatic haemosiderosis in Wilson's disease 680
Dosage of the hepatic copper in the normal range in a patient affected by Wilson’s disease. 636
Peginterferon alpha-2a (40kD) monotherapy vs peginterferon alpha-2a and ribavirin in naive patients with chronic hepatitis C: Preliminary results of the SMIEC II trial in patients with early viral clearance on peginterferon monotherapy 618
Syncitial giant cell hepatitis: a new form of chronic liver disease 586
Wilson’s disease with late onset 571
Unusual evolution from overt autoimmune hypothyroidism to hyperthyroidism after IFN-α therapy for chronic hepatitis. 570
Enhanced response to peginterferon-alpha-2a-based triple therapy in previously non-responsive chronic hepatitis C: Final results of pretty study RID E-8970-2010 564
Epidemiologic study of hepatolenticular degeneration (Wilson's disease) in Sardinia (1902-1983) 547
Chronic viral hepatitis in Hiv + drug addicts 529
Computerized cranial tomography in presymptomatic and hepatic form of Wilson's disease 525
null 520
Final results of the SMIEC trial in natve patients with hepatitis C: Double therapy (peginterferonalfa2a+ribavirin) vs peginterferon monotherapy in early viral responders and vs triple therapy (peginterferon plus ribavirin plus amantadine) in early non responders 506
Syncitial giant cell hepatitis. A case report 503
HCV transmission in family members of subjects with HCV related chronic liver disease 485
Predictive testing for Wilson's disease using tightly linked and flanking DNA markers 475
alpha 2 Antiplasmin and disseminated intravascular coagulation in liver cirrhosis 463
Wilson's disease maps between the D13S169 and D13S173 loci 453
[Plasma prekallikrein (Fletcher factor) in hepatic cirrhosis]. FT La precallicreina plasmatica (fattore Fletcher) nella cirrosi epatica. 451
Diagnostic value of 24 hr urinary copper excretion after penicillamine challenge in the adult Wilson's disease patients. 445
Coagulazione, fibrinolisi e shunt porto-sistemico nelle epatopatie croniche 431
Ductular reaction and oval cell prolipheration in chronic hepatitis C. 430
HDL-cholesterol in chronic uremia during hemodialytic treatment 420
IS INTRAPULMONARY SHUNT IN CIRRHOTIC-PATIENTS CORRELATED WITH PORTACAVAL-SHUNT 414
A randomized controlled trial of amantadine plus interferon alpha-2a vs interferon-alpha-2a in naive patients with chronic hepatitis C randomized based on early response to interferon alpha-2a alone. 388
Idiopathic adulthood ductopenia presenting with chronic recurrent cholestasis. A case report 385
Usefulness and limitations of determination of lactate dehydrogenase enzymes in the diagnosis of liver diseases 373
Pseudo-porphyria cutanea tarda in patients hemodialyzed for chronic renal insufficiency. Clinical, metabolic and immunological aspect 371
Comparison of MRI, EEG, EPs and ECD-SPECT in Wilson's disease 346
Hypothalamo-pituitary-adrenal function in liver cirrhosis of viral etilogy 326
ABNORMAL PULMONARY EPITHELIAL PERMEABILITY IN LIVER-CIRRHOSIS 296
The role of a double liver needle biopsy in the diagnosis of Wilson's disease. 289
Efficacy of lamivudine in patients with antiHBe plus chronic active hepatitis B. 272
Transient elastography in patients with chronic autoimmune hepatitis: is a goog tool in evaluation of hepatic fibrosis? 267
Efficacy and safety of long-term IFN therapy in active chronic hepatitis D: Six years of sustained response to the treatment. Case report. 256
Diagnostic value of histochemical stains for copper in Wilson's disease 229
Serum ALT level, phlebotomy treatment and alpha-interferon therapy in chronic hepatitis C. 207
Totale 101.190
Salva come PNG Salva come JPEG
Categoria #
all - tutte 120.445
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 120.445
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019776 0 0 0 0 0 0 0 0 0 0 380 396
2019/202021.315 1.065 643 143 308 8.018 5.484 2.867 678 396 374 426 913
2020/202126.940 807 1.072 1.118 7.236 5.636 3.298 2.232 1.657 514 1.476 1.124 770
2021/20227.452 652 615 443 495 513 825 601 319 419 514 902 1.154
2022/20238.388 993 1.192 1.086 737 831 914 320 665 385 416 485 364
2023/20246.208 491 421 320 788 762 1.091 953 480 343 536 23 0
Totale 101.190